VivoSeq
Infectious Disease

Herpes Simplex Infection

9

Pipeline Programs↗

0

Active Trials↗

6

Companies Involved↗

Herpes simplex infection is an early-stage landscape with 9 programs across 6 companies. The most active players are Sanofi, Novartis, Glaxo Dba Glaxosmithkline. 5 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

63/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 3G

Glaxo Dba Glaxosmithkline

1 program

ApprovedGilead logo

Gilead

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

ApprovedQ

Quince Therapeutics S.p.A.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Completed2 · 100%

Clinical Trials

Trial Activity

Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection
Completed·Novartis logoNovartis·Phase 3·NCT00098059·74 enrolled
Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection
Completed·Novartis logoNovartis·Phase 2·NCT00448227·18 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)